Mantle Cell Lymphoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：250頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Mantle Cell Lymphoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Mantle Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Mantle Cell Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Mantle Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Mantle Cell Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Mantle Cell Lymphoma Overview 11
Therapeutics Development 12
Pipeline Products for Mantle Cell Lymphoma - Overview 12
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 13
Mantle Cell Lymphoma - Therapeutics under Development by Companies 14
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 18
Mantle Cell Lymphoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Mantle Cell Lymphoma - Products under Development by Companies 23
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 25
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 26
Amgen Inc. 26
Eli Lilly and Company 27
GlaxoSmithKline plc 28
Gilead Sciences, Inc. 29
Merck & Co., Inc. 30
Infinity Pharmaceuticals, Inc. 31
Piramal Enterprises Limited 32
Millennium Pharmaceuticals, Inc. 33
Novartis AG 34
Astellas Pharma Inc. 35
BioMarin Pharmaceutical Inc. 36
ImmunoGen, Inc. 37
Pfizer Inc. 38
Astex Pharmaceuticals, Inc. 39
Teva Pharmaceutical Industries Limited 40
Cell Therapeutics, Inc. 41
Celgene Corporation 42
Onyx Pharmaceuticals, Inc. 43
Celldex Therapeutics, Inc. 44
Accentia Biopharmaceuticals, Inc. 45
Portola Pharmaceuticals, Inc. 46
Pharmacyclics, Inc. 47
Senesco Technologies, Inc. 48
Memgen, LLC. 49
Stemline Therapeutics, Inc. 50
Onconova Therapeutics, Inc. 51
LFB Biotechnologies, S.A.S 52
Advancell 53
Selvita S.A 54
AbbVie Inc. 55
Amgen Astellas BioPharma K.K. 56
Mantle Cell Lymphoma - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Target 58
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
ibrutinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
bortezomib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
bendamustine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pacritinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
abexinostat hydrochloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
agatolimod sodium - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
dasiprotimut T - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
AT-7519 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
carfilzomib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
idelalisib - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ISF-35 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
P-1446 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
CTL-019 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
vorinostat - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
buparlisib hydrochloride - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
lenalidomide - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
LY-2835219 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
ublituximab - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
GS-9973 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
SNS-01T - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
PRT-2070 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Allogeneic CD19CAR-TCM cells - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
CEP-9722 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
pevonedistat hydrochloride - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
CDX-1127 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
rigosertib sodium - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
ON-013105 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
palbociclib - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
NSC-678515 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
LEE-011 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
duvelisib - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
BMN-673 - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
AMG-319 - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
IMGN-529 - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
ABT-199 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
acadesine - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
SL-101 - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
8-chloroadenosine - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
SEL-120 - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
BLyS-Gelonin Fusion Toxin - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
ONC-201 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
tretinoin - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
Andrographolide - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
blinatumomab - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Mantle Cell Lymphoma - Recent Pipeline Updates 156
Mantle Cell Lymphoma - Dormant Projects 239
Mantle Cell Lymphoma - Discontinued Products 240
Mantle Cell Lymphoma - Product Development Milestones 241
Featured News & Press Releases 241
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Marqibo at the 55th Annual Meeting of the American Society of Hematology 241
Nov 19, 2013: Impressive Results from ibrutinib Study Conducted at John Theurer Cancer Center Lead to FDA Approval of Imbruvica as a Single Agent for Patients with Mantle Cell Lymphoma 241
Nov 15, 2013: Diplomat receives limited distribution contract for IMBRUVICA 242
Nov 13, 2013: IMBRUVICA Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy 243
Nov 12, 2013: Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting 244
Oct 30, 2013: New Marketing Authorisation Application Submitted to EMA for Ibrutinib for the Treatment of Two Forms of Blood Cancer 245
Sep 26, 2013: John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001 Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma Patients 246
Aug 29, 2013: New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA 246
Aug 22, 2013: Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology 247
Jul 10, 2013: New Drug Application for Ibrutinib Submitted to the U.S. FDA 248
Appendix 249
Methodology 249
Coverage 249
Secondary Research 249
Primary Research 249
Expert Panel Validation 249
Contact Us 250
Disclaimer 250
List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H1 2014 12
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Development by Companies, H1 2014 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Development, H1 2014 21
Comparative Analysis by Unknown Stage Development, H1 2014 22
Products under Development by Companies, H1 2014 23
Products under Development by Companies, H1 2014 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H1 2014 26
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H1 2014 27
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H1 2014 28
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 29
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 30
Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 31
Mantle Cell Lymphoma - Pipeline by Piramal Enterprises Limited, H1 2014 32
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 33
Mantle Cell Lymphoma - Pipeline by Novartis AG, H1 2014 34
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014 35
Mantle Cell Lymphoma - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 36
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 37
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H1 2014 38
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 39
Mantle Cell Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 40
Mantle Cell Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014 41
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H1 2014 42
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 43
Mantle Cell Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2014 44
Mantle Cell Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 45
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 46
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 47
Mantle Cell Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014 48
Mantle Cell Lymphoma - Pipeline by Memgen, LLC., H1 2014 49
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2014 50
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2014 51
Mantle Cell Lymphoma - Pipeline by LFB Biotechnologies, S.A.S, H1 2014 52
Mantle Cell Lymphoma - Pipeline by Advancell, H1 2014 53
Mantle Cell Lymphoma - Pipeline by Selvita S.A, H1 2014 54
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H1 2014 55
Mantle Cell Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 56
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Stage and Target, H1 2014 60
Number of Products by Stage and Mechanism of Action, H1 2014 64
Number of Products by Stage and Route of Administration, H1 2014 67
Number of Products by Stage and Molecule Type, H1 2014 69
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 156
Mantle Cell Lymphoma - Dormant Projects, H1 2014 239
Mantle Cell Lymphoma - Discontinued Products, H1 2014 240
List of Figures
Number of Products under Development for Mantle Cell Lymphoma, H1 2014 12
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Products, H1 2014 21
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Top 10 Target, H1 2014 58
Number of Products by Stage and Top 10 Target, H1 2014 59
Number of Products by Top 10 Mechanism of Action, H1 2014 62
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 63
Number of Products by Top 10 Route of Administration, H1 2014 66
Number of Products by Stage and Top 10 Route of Administration, H1 2014 67
Number of Products by Top 10 Molecule Type, H1 2014 68
Number of Products by Stage and Top 10 Molecule Type, H1 2014 69
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Mantle Cell Lymphoma Overview 11
Therapeutics Development 12
Pipeline Products for Mantle Cell Lymphoma - Overview 12
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis 13
Mantle Cell Lymphoma - Therapeutics under Development by Companies 14
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 18
Mantle Cell Lymphoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Mantle Cell Lymphoma - Products under Development by Companies 23
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes 25
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development 26
Amgen Inc. 26
Eli Lilly and Company 27
GlaxoSmithKline plc 28
Gilead Sciences, Inc. 29
Merck & Co., Inc. 30
Infinity Pharmaceuticals, Inc. 31
Piramal Enterprises Limited 32
Millennium Pharmaceuticals, Inc. 33
Novartis AG 34
Astellas Pharma Inc. 35
BioMarin Pharmaceutical Inc. 36
ImmunoGen, Inc. 37
Pfizer Inc. 38
Astex Pharmaceuticals, Inc. 39
Teva Pharmaceutical Industries Limited 40
Cell Therapeutics, Inc. 41
Celgene Corporation 42
Onyx Pharmaceuticals, Inc. 43
Celldex Therapeutics, Inc. 44
Accentia Biopharmaceuticals, Inc. 45
Portola Pharmaceuticals, Inc. 46
Pharmacyclics, Inc. 47
Senesco Technologies, Inc. 48
Memgen, LLC. 49
Stemline Therapeutics, Inc. 50
Onconova Therapeutics, Inc. 51
LFB Biotechnologies, S.A.S 52
Advancell 53
Selvita S.A 54
AbbVie Inc. 55
Amgen Astellas BioPharma K.K. 56
Mantle Cell Lymphoma - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Target 58
Assessment by Mechanism of Action 62
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
ibrutinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
bortezomib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
bendamustine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pacritinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
abexinostat hydrochloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
agatolimod sodium - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
dasiprotimut T - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
AT-7519 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
carfilzomib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
idelalisib - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ISF-35 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
P-1446 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
CTL-019 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
vorinostat - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
buparlisib hydrochloride - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
lenalidomide - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
LY-2835219 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
ublituximab - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
GS-9973 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
SNS-01T - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
PRT-2070 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Allogeneic CD19CAR-TCM cells - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
CEP-9722 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
pevonedistat hydrochloride - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
CDX-1127 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
rigosertib sodium - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
ON-013105 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
palbociclib - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
NSC-678515 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
LEE-011 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
duvelisib - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
BMN-673 - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
AMG-319 - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
IMGN-529 - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
ABT-199 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
acadesine - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
SL-101 - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
8-chloroadenosine - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
SEL-120 - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
BLyS-Gelonin Fusion Toxin - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
ONC-201 - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
tretinoin - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
Andrographolide - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
blinatumomab - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Mantle Cell Lymphoma - Recent Pipeline Updates 156
Mantle Cell Lymphoma - Dormant Projects 239
Mantle Cell Lymphoma - Discontinued Products 240
Mantle Cell Lymphoma - Product Development Milestones 241
Featured News & Press Releases 241
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Marqibo at the 55th Annual Meeting of the American Society of Hematology 241
Nov 19, 2013: Impressive Results from ibrutinib Study Conducted at John Theurer Cancer Center Lead to FDA Approval of Imbruvica as a Single Agent for Patients with Mantle Cell Lymphoma 241
Nov 15, 2013: Diplomat receives limited distribution contract for IMBRUVICA 242
Nov 13, 2013: IMBRUVICA Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy 243
Nov 12, 2013: Senesco to Provide Update on Its Phase 1b/2a Trial Progress at 55th American Society of Hematology Annual Meeting 244
Oct 30, 2013: New Marketing Authorisation Application Submitted to EMA for Ibrutinib for the Treatment of Two Forms of Blood Cancer 245
Sep 26, 2013: John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001 Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma Patients 246
Aug 29, 2013: New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA 246
Aug 22, 2013: Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology 247
Jul 10, 2013: New Drug Application for Ibrutinib Submitted to the U.S. FDA 248
Appendix 249
Methodology 249
Coverage 249
Secondary Research 249
Primary Research 249
Expert Panel Validation 249
Contact Us 250
Disclaimer 250
List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H1 2014 12
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Development by Companies, H1 2014 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Development, H1 2014 21
Comparative Analysis by Unknown Stage Development, H1 2014 22
Products under Development by Companies, H1 2014 23
Products under Development by Companies, H1 2014 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H1 2014 26
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H1 2014 27
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H1 2014 28
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 29
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 30
Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 31
Mantle Cell Lymphoma - Pipeline by Piramal Enterprises Limited, H1 2014 32
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 33
Mantle Cell Lymphoma - Pipeline by Novartis AG, H1 2014 34
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014 35
Mantle Cell Lymphoma - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 36
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 37
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H1 2014 38
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 39
Mantle Cell Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 40
Mantle Cell Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014 41
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H1 2014 42
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 43
Mantle Cell Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2014 44
Mantle Cell Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 45
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 46
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 47
Mantle Cell Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014 48
Mantle Cell Lymphoma - Pipeline by Memgen, LLC., H1 2014 49
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2014 50
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2014 51
Mantle Cell Lymphoma - Pipeline by LFB Biotechnologies, S.A.S, H1 2014 52
Mantle Cell Lymphoma - Pipeline by Advancell, H1 2014 53
Mantle Cell Lymphoma - Pipeline by Selvita S.A, H1 2014 54
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H1 2014 55
Mantle Cell Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 56
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Stage and Target, H1 2014 60
Number of Products by Stage and Mechanism of Action, H1 2014 64
Number of Products by Stage and Route of Administration, H1 2014 67
Number of Products by Stage and Molecule Type, H1 2014 69
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 156
Mantle Cell Lymphoma - Dormant Projects, H1 2014 239
Mantle Cell Lymphoma - Discontinued Products, H1 2014 240
List of Figures
Number of Products under Development for Mantle Cell Lymphoma, H1 2014 12
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Products, H1 2014 21
Assessment by Monotherapy Products, H1 2014 57
Number of Products by Top 10 Target, H1 2014 58
Number of Products by Stage and Top 10 Target, H1 2014 59
Number of Products by Top 10 Mechanism of Action, H1 2014 62
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 63
Number of Products by Top 10 Route of Administration, H1 2014 66
Number of Products by Stage and Top 10 Route of Administration, H1 2014 67
Number of Products by Top 10 Molecule Type, H1 2014 68
Number of Products by Stage and Top 10 Molecule Type, H1 2014 69
